The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Imigran     butanedioic acid; 1-[3-(2...

Synonyms: Arcoiran, Imigrane, Megrelan, Migratan, Novelian, ...
This record was replaced with 5358.
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Imigran

 

High impact information on Imigran

  • Sumatriptan succinate, a 5-HT1D receptor agonist, constricts human cranial arteries [1].
  • The introduction in 1991 of sumatriptan succinate, the first approved 5-HT1B/1D receptor agonist, represented a significant advance in the treatment of acute migraine [6].
  • In this crossover design study, 24 healthy subjects received the following four treatments, each separated by at least 7 days: 1 mg butorphanol (Stadol NS7); 20 mg sumatriptan (Imitrex Nasal Spray); or both formulations together with butorphanol administered either 1 or 30 min after sumatriptan [7].
  • It was found that side-effects induced acutely by injection of 6 mg sumatriptan succinate s.c. were associated with reduced oxygen storage in peripheral skeletal muscle 5-20 min after injection as demonstrated by a transient reduction in mitochondrial function at end-exercise [8].
  • The effects of percutaneous enhancers on the transdermal absorption of sumatriptan succinate were investigated by in vitro permeation studies [9].
 

Chemical compound and disease context of Imigran

 

Biological context of Imigran

 

Associations of Imigran with other chemical compounds

  • Given the average elimination half-life of 2 hr for sumatriptan, it is evident that only very small amounts of the agent will cross from mother to fetus after single doses of Imitrex [12].
 

Gene context of Imigran

  • Sumatriptan (CAS 103628-46-2, 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide++ +), a substance for treatment of acute migraine attacks, and its main metabolite are investigated by thinlayer chromatography (TLC), ultraviolet spectroscopy, and gas chromatography/mass spectrometry (GC/MS) [15].
 

Analytical, diagnostic and therapeutic context of Imigran

  • Two hundred forty-two adult migraineurs participated in a randomized, double-blind study in which one dose of 1, 2, 3, 4, 6, or 8 mg of subcutaneous sumatriptan succinate was evaluated in sequential ascending fashion [16].
  • PATIENT: A 43-year-old man who developed a left occipital infarct after taking a total of 23 sumatriptan succinate tablets (25 mg per tablet) and 32 Midrin tablets during a 7-day period and who on digital subtraction angiography was shown to have segmental cerebral arterial narrowing in multiple vessels [17].
  • Determination of sumatriptan succinate in plasma and urine by high-performance liquid chromatography with electrochemical detection [18].
  • The efficacy and tolerability of subcutaneous (SC) sumatriptan administered with the IMITREX (sumatriptan succinate) STATdose System, which circumvents the need for patients or health care professionals to handle a syringe, were evaluated in two randomized, double-masked, parallel-group, placebo-controlled, multicenter studies [19].
  • A high performance liquid chromatographic (HPLC) method for the assay of sumatriptan succinate residues in swabs collected from manufacturing equipment surfaces was developed and validated in order to control a cleaning procedure [20].

References

  1. Treatment of acute migraine with subcutaneous sumatriptan. Cady, R.K., Wendt, J.K., Kirchner, J.R., Sargent, J.D., Rothrock, J.F., Skaggs, H. JAMA (1991) [Pubmed]
  2. The association of the combination of sumatriptan and methysergide in myocardial infarction in a premenopausal woman. Liston, H., Bennett, L., Usher, B., Nappi, J. Arch. Intern. Med. (1999) [Pubmed]
  3. Oral sumatriptan-associated transmural myocardial infarction. O'Connor, P., Gladstone, P. Neurology (1995) [Pubmed]
  4. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Winner, P., Ricalde, O., Le Force, B., Saper, J., Margul, B. Arch. Neurol. (1996) [Pubmed]
  5. Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache. Dahlöf, C., Ekbom, K., Persson, L. Arch. Neurol. (1994) [Pubmed]
  6. Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials. Tfelt-Hansen, P., Ryan, R.E. Neurology (2000) [Pubmed]
  7. A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration. Vachharajani, N.N., Shyu, W.C., Nichola, P.S., Boulton, D.W. Cephalalgia : an international journal of headache. (2002) [Pubmed]
  8. Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects. Boska, M.D., Welch, K.M., Schultz, L., Nelson, J. Cephalalgia : an international journal of headache. (2000) [Pubmed]
  9. Effect of chemical enhancers on the in vitro percutaneous absorption of sumatriptan succinate. Femenía-Font, A., Balaguer-Fernández, C., Merino, V., Rodilla, V., López-Castellano, A. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V. (2005) [Pubmed]
  10. Oral sumatriptan for the long-term treatment of migraine: clinical findings. Rederich, G., Rapoport, A., Cutler, N., Hazelrigg, R., Jamerson, B. Neurology (1995) [Pubmed]
  11. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. Visser, W.H., Terwindt, G.M., Reines, S.A., Jiang, K., Lines, C.R., Ferrari, M.D. Arch. Neurol. (1996) [Pubmed]
  12. Sumatriptan (Imitrex) transport by the human placenta. Schenker, S., Yang, Y., Perez, A., Henderson, G.I., Lee, M.P. Proc. Soc. Exp. Biol. Med. (1995) [Pubmed]
  13. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Freitag, F.G., Cady, R., DiSerio, F., Elkind, A., Gallagher, R.M., Goldstein, J., Klapper, J.A., Rapoport, A.M., Sadowsky, C., Saper, J.R., Smith, T.R. Headache. (2001) [Pubmed]
  14. Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. Vyas, T.K., Babbar, A.K., Sharma, R.K., Singh, S., Misra, A. AAPS PharmSciTech [electronic resource]. (2006) [Pubmed]
  15. Screening and identification of sumatriptan and its main metabolite by means of thin-layer chromatography, ultraviolet spectroscopy and gas chromatography/mass spectrometry. Rochholz, G., Ahrens, B., König, F., Schütz, H.W., Schütz, H., Seno, H. Arzneimittel-Forschung. (1995) [Pubmed]
  16. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Mathew, N.T., Dexter, J., Couch, J., Flamenbaum, W., Goldstein, J., Rapoport, A., Sheftell, F., Saper, J., Silberstein, S., Solomon, S. Arch. Neurol. (1992) [Pubmed]
  17. Reversible segmental cerebral arterial vasospasm and cerebral infarction: possible association with excessive use of sumatriptan and Midrin. Meschia, J.F., Malkoff, M.D., Biller, J. Arch. Neurol. (1998) [Pubmed]
  18. Determination of sumatriptan succinate in plasma and urine by high-performance liquid chromatography with electrochemical detection. Andrew, P.D., Birch, H.L., Phillpot, D.A. Journal of pharmaceutical sciences. (1993) [Pubmed]
  19. Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System. Mushet, G.R., Cady, R.K., Baker, C.C., Clements, B., Gutterman, D.L., Davis, R. Clinical therapeutics. (1996) [Pubmed]
  20. Development and validation of an LC assay for sumatriptan succinate residues on surfaces in the manufacture of pharmaceuticals. Nozal, M.J., Bernal, J.L., Toribio, L., Martín, M.T., Diez, F.J. Journal of pharmaceutical and biomedical analysis. (2002) [Pubmed]
 
WikiGenes - Universities